Impact of facility type and volume on survival in patients with metastatic renal cell carcinoma

Furkan Dursun, Ahmed Elshabrawy, Hanzhang Wang, James Oelsen, Michael A Liss, Dharam Kaushik, Chethan Ramamurthy, Ronald Rodriguez, Ahmed M Mansour Elkenany

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: To investigate the impact of facility type and volume on survival in patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: We investigated the National Cancer Database for patients with mRCC. Patients were stratified according to treatment facility type (academic vs. non-academic) and facility volume (high, intermediate, and low). Kaplan-Meier survival estimates and Cox proportional hazard models were fitted to evaluate overall survival (OS) as a function of facility type, volume, and different treatment modalities. RESULTS: A total of 27,598 patients were identified, of which 10,938 (40%) were treated at academic centers (AC) and 16,131 (60%) at non-academic centers (non-AC). Overall, 19,904 patients (72%) were treated in high-volume hospitals (HVH). Among patients treated at AC, 94% were treated at HVHs. Patients treated at AC were more likely to receive immunotherapy, undergo cytoreductive nephrectomy (CN) and metastasectomy. The 2 and 5 year OS rates for patients treated in AC were 29.7% (CI 28.8%-30.6%) and 13% (CI 12%-14%) vs. 21.7% (CI 21%-22.4%) and 8.4% (CI %7.91-%8.99) in the Non-AC, respectively (p < 0.001). Multivariate Cox regression analysis identified treatment at AC as an independent predictor of survival (HR 0.85, 95% CI 0.81-0.91, p < 0.001). Undergoing CN and receipt of immunotherapy was also associated with a survival benefit (HR 0.41, CI 0.40-0.43 and HR 0.63, CI 0.59-0.68 respectively, p < 0.001). CONCLUSIONS: Treatment at ACs and HVHs was associated with a survival benefit in patients with mRCC. Patients treated at AC were more likely to receive immunotherapy, undergo CN and metastasectomy.

Original languageEnglish (US)
Pages (from-to)10806-10816
Number of pages11
JournalThe Canadian journal of urology
Volume28
Issue number5
StatePublished - Oct 1 2021

Keywords

  • academic center
  • cytoreductive nephrectomy
  • high volume
  • immunotherapy
  • metastasectomy

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Impact of facility type and volume on survival in patients with metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this